Malaria is a disease which has had a devastating impact on human health for centuries. Currently over one-third of the world’s population is at risk, with and estimated 300 million cases and 650,000 deaths worldwide each year. Students taking this course will learn about this disease from the basic biological, public health, and clinical perspectives. The class is divided into eight subject areas:
- The Disease
- The Parasite
- Drug Resistance
- On the Horizon
Using pre-recorded lectures for each of these areas, combined with selected online content and exams, students successfully completing this course will possess a foundational knowledge of malaria, preparing them for a future in public health, policy, research, and clinical arenas.
- Students will become knowledgeable on the history and impact of malaria on the world’s population
- Students will gain the foundational knowledge necessary to comprehend the basic biology of the eukaryotic parasite that causes malaria, including its lifecycle between the insect vector and the human host
- Students will learn the current status of diagnostic, therapeutic, vaccination, and intervention approaches.
- Students will be familiar with available online resources to guide sound decision making in the clinical setting
- Students will appreciate the difficulty in preventing, treating, and eradicating malaria and the current approaches being developed to achieve these goals.
About the Instructor
Mark E. Drew, PhD
Dr. Mark Drew earned his Bachelor’s degree in chemistry from Seattle Pacific University and then joined the Seattle Biomedical Research Institute as a research technician working with Dr. Jean Feagin studying the mitochondrial genome of Plasmodium falciparum. Following this Mark continued as a technician at Oregon Health Sciences University with Dr. Scott Landfear studying nucleoside transporters in Leishmania. For his Ph.D. studies, Mark attended The Johns Hopkins University School of Medicine, studying in the Department of Biological Chemistry under the mentorship of Dr. Paul Englund, working on the mitochondrial DNA network of trypanosomes. After being awarded his Ph.D., Mark joined the laboratory of Dr. Daniel Goldberg at Washington University in St. Louis for his postdoctoral research, returning to work on Plasmodium, focusing his efforts on the development of therapeutics for treating human malaria. In the fall of 2008, Mark joined The Ohio State University as an Assistant Professor where he is currently a member of the Department of Microbial Infection and Immunity.